Supplementary Table 1 for Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration’s September 1,2021, data safety communication

Published: 27 April 2022| Version 1 | DOI: 10.17632/m23y6ryhv7.1
Contributor:
Jonathan Rick

Description

Supplementary Table 1 for Special editorial: When prescribing Janus kinase inhibitors for dermatologic conditions, be mindful of the Food and Drug Administration’s September 1,2021, data safety communication.

Files

Categories

Dermatology

Licence